James Brugarolas
Overview
Explore the profile of James Brugarolas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
6754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gulati S, Barata P, Elliott A, Bilen M, Burgess E, Choueiri T, et al.
J Clin Invest
. 2024 Jul;
134(14).
PMID: 39007269
BACKGROUNDMetastases are the hallmark of lethal cancer, though underlying mechanisms that drive metastatic spread to specific organs remain poorly understood. Renal cell carcinoma (RCC) is known to have distinct sites...
12.
Yang J, Butti R, Cohn S, Toffessi-Tcheuyap V, Mal A, Nguyen M, et al.
Proc Natl Acad Sci U S A
. 2024 Jun;
121(25):e2310793121.
PMID: 38861592
mTORC1 is aberrantly activated in renal cell carcinoma (RCC) and is targeted by rapalogs. As for other targeted therapies, rapalogs clinical utility is limited by the development of resistance. Resistance...
13.
Jasti J, Zhong H, Panwar V, Jarmale V, Miyata J, Carrillo D, et al.
ArXiv
. 2024 Jun;
PMID: 38855551
Background: Predictive biomarkers of treatment response are lacking for metastatic clearcell renal cell carcinoma (ccRCC), a tumor type that is treated with angiogenesis inhibitors, immune checkpoint inhibitors, mTOR inhibitors and...
14.
Khaleel S, Ricketts C, Linehan W, Ball M, Manley B, Turajilic S, et al.
Soc Int Urol J
. 2024 Jun;
3(6):386-396.
PMID: 38840811
Renal cell carcinoma is a diverse group of diseases that can be distinguished by distinct histopathologic and genomic features. In this comprehensive review, we highlight recent advancements in our understanding...
15.
Tran D, Kim D, Kesavan R, Brown H, Dey T, Soflaee M, et al.
Cell
. 2024 Jun;
187(14):3602-3618.e20.
PMID: 38823389
Purine nucleotides are vital for RNA and DNA synthesis, signaling, metabolism, and energy homeostasis. To synthesize purines, cells use two principal routes: the de novo and salvage pathways. Traditionally, it...
16.
Kapur P, Zhong H, Le D, Mukhopadhyay R, Miyata J, Carrillo D, et al.
JCI Insight
. 2024 May;
9(10).
PMID: 38775158
Sarcomatoid dedifferentiation is common to multiple renal cell carcinoma (RCC) subtypes, including chromophobe RCC (ChRCC), and is associated with increased aggressiveness, resistance to targeted therapies, and heightened sensitivity to immunotherapy....
17.
Calhoon D, Sang L, Bezwada D, Kim N, Basu A, Hsu S, et al.
bioRxiv
. 2024 May;
PMID: 38765991
Lipids are essential for tumours because of their structural, energetic, and signaling roles. While many cancer cells upregulate lipid synthesis, growing evidence suggests that tumours simultaneously intensify the uptake of...
18.
Simoni M, Menegazzi C, Fracassi C, Biffi C, Genova F, Tenace N, et al.
EMBO Mol Med
. 2024 May;
16(6):1324-1351.
PMID: 38730056
Clear-cell renal cell carcinoma (ccRCC), the major subtype of RCC, is frequently diagnosed at late/metastatic stage with 13% 5-year disease-free survival. Functional inactivation of the wild-type p53 protein is implicated...
19.
Brugarolas J, Obara G, Beckermann K, Rini B, Lam E, Hamilton J, et al.
Clin Cancer Res
. 2024 Apr;
30(11):2402-2411.
PMID: 38652038
Purpose: ARO-HIF2 is an siRNA drug designed to selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). The aims of this Phase 1...
20.
Wang D, Mahmud I, Thakur V, Tan S, Isom D, Lombard D, et al.
Cancer Res
. 2024 Apr;
84(13):2141-2154.
PMID: 38640229
Clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, is largely incurable in the metastatic setting. ccRCC is characterized by excessive lipid accumulation that protects cells...